These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37878345)

  • 1. Spatial Transcriptomics Suggests That Alterations Occur in the Preneoplastic Breast Microenvironment of BRCA1/2 Mutation Carriers.
    Caputo A; Vipparthi K; Bazeley P; Downs-Kelly E; McIntire P; Duckworth LA; Ni Y; Hu B; Keri RA; Karaayvaz M
    Mol Cancer Res; 2024 Feb; 22(2):169-180. PubMed ID: 37878345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in the preneoplastic breast microenvironment of
    Caputo A; Vipparthi K; Bazeley P; Downs-Kelly E; McIntire P; Ni Y; Hu B; Keri RA; Karaayvaz M
    bioRxiv; 2023 May; ():. PubMed ID: 37292816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene.
    Bhat-Nakshatri P; Khatpe AS; Chen D; Batic K; Mang H; Herodotou C; McGuire PC; Xuei X; Erdogan C; Gao H; Liu Y; Sandusky G; Storniolo AM; Nakshatri H
    Cancer Res Commun; 2024 Jan; 4(1):38-54. PubMed ID: 38059556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
    Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
    Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
    BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
    Zhang J; Sun J; Chen J; Yao L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2016 Aug; 158(3):455-62. PubMed ID: 27393621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
    Li G; Guo X; Tang L; Chen M; Luo X; Peng L; Xu X; Wang S; Xiao Z; Yi W; Dai L; Wang J
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2011-2024. PubMed ID: 28664449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.
    Sun S; Brazhnik K; Lee M; Maslov AY; Zhang Y; Huang Z; Klugman S; Park BH; Vijg J; Montagna C
    J Clin Invest; 2022 Mar; 132(5):. PubMed ID: 35025760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
    Yao L; Sun J; Zhang J; He Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2016 Apr; 156(3):441-445. PubMed ID: 27033093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
    Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
    PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
    Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
    Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
    Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
    Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
    Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
    Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.
    ; ;
    Breast Cancer Res Treat; 2008 May; 109(1):67-75. PubMed ID: 17972172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.